Adma Biologics Inc [NASDAQ: ADMA] stock went on a downward path that fall over -1.74% on Wednesday, amounting to a one-week price decrease of less than -1.17%.
Over the last 12 months, ADMA stock dropped by -1.46%. The one-year Adma Biologics Inc stock forecast points to a potential upside of 47.73. The average equity rating for ADMA stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $4.03 billion, with 239.38 million shares outstanding and 230.45 million shares in the current float. Compared to the average trading volume of 3.14M shares, ADMA stock reached a trading volume of 5810438 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Adma Biologics Inc [ADMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADMA shares is $32.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADMA stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Adma Biologics Inc shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on July 19, 2023. While these analysts kept the previous recommendation, Mizuho raised their target price to Buy. The new note on the price target was released on October 13, 2022, representing the official price target for Adma Biologics Inc stock. Previously, the target price had yet another raise to $5, while Raymond James analysts kept a Strong Buy rating on ADMA stock.
The Price to Book ratio for the last quarter was 10.16, with the Price to Cash per share for the same quarter was set at 0.38. Price to Free Cash Flow for ADMA in the course of the last twelve months was 61.32 with Quick ratio for the last quarter at 2.78.
ADMA Stock Performance Analysis:
Adma Biologics Inc [ADMA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.17. With this latest performance, ADMA shares dropped by -15.12% in over the last four-week period, additionally sinking by -0.65% over the last 6 months – not to mention a drop of -1.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMA stock in for the last two-week period is set at 43.17, with the RSI for the last a single of trading hit 0.60, and the three-weeks RSI is set at 0.71 for Adma Biologics Inc [ADMA]. The present Moving Average for the last 50 days of trading for this stock 17.72, while it was recorded at 17.20 for the last single week of trading, and 18.69 for the last 200 days.
Insight into Adma Biologics Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Adma Biologics Inc [ADMA] shares currently have an operating margin of 32.82% and a Gross Margin at 52.98%. Adma Biologics Inc’s Net Margin is presently recorded at 44.06%.
Adma Biologics Inc (ADMA) Capital Structure & Debt Analysis
According to recent financial data for Adma Biologics Inc. ( ADMA), the Return on Equity (ROE) stands at 71.23%, highlighting impressive shareholder gains. The Return on Assets (ROA) is 44.70%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Adma Biologics Inc’s Return on Invested Capital (ROIC) is 43.43%, showcasing its effectiveness in deploying capital for earnings.
Adma Biologics Inc (ADMA) Efficiency & Liquidity Metrics
Based on Adma Biologics Inc’s (ADMA) latest financial statements, the Debt-to-Equity Ratio is 0.21%, indicating its reliance on debt financing relative to shareholder equity.
Adma Biologics Inc (ADMA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Adma Biologics Inc. (ADMA) effectively leverages its workforce, generating an average of $305007.3 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.33% and a Quick Ratio of 2.78%, indicating strong ability to cover short-term liabilities.
ADMA Stock EPS
With the latest financial reports released by the company, Adma Biologics Inc posted 0.15/share EPS, while the average EPS was predicted by analysts to be reported at 0.13/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADMA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adma Biologics Inc go to 30.15%.
Adma Biologics Inc [ADMA] Institutonal Ownership Details
There are presently around $90.73%, or 93.12%% of ADMA stock, in the hands of institutional investors. The top three institutional holders of ADMA stocks are: BLACKROCK INC. with ownership of 18.64 million shares, which is approximately 8.0221%. VANGUARD GROUP INC, holding 14.52 million shares of the stock with an approximate value of $$162.3 million in ADMA stocks shares; and VANGUARD GROUP INC, currently with $$147.25 million in ADMA stock with ownership which is approximately 5.6668%.
